Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 20, 2020Seminars in Thrombosis and HemostasisOpen Access

Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Reversal strategies for direct factor Xa inhibitors have been a focal point in clinical care to restore hemostasis during bleeding or emergency surgery.

Comparison

Nonspecific vs specific reversal agents for direct factor Xa inhibitors

Design

Review

Authors

MSMark SchreuderPRPieter H. ReitsmaMBMettine H.A. Bos

Discussion

Loading...

Member takes

Overview

Reversal strategies for factor Xa inhibitors remain incompletely standardized; leaves open need for prospective trials to guide emergency use.

Structured PICO

P
Population
Patients on direct factor Xa inhibitors or direct thrombin inhibitors for venous thromboembolism or nonvalvular atrial fibrillation requiring reversal due to bleeding or emergency surgery
I
Intervention
Specific and nonspecific reversal agents for direct factor Xa inhibitors (including prothrombin complex concentrate and recombinant factor VIIa)

This review provides a comprehensive overview of the biochemical mechanisms and current development state of reversal agents for direct factor Xa inhibitors.

Cite This Study

Schreuder et al. (2020) studied this question.

synapsesocial.com/papers/6a7d08b8ff1a536db837cbe8https://doi.org/10.1055/s-0040-1709134
View Full Paper
Ask AI
Bookmark
Share